FI3565551T3 - Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä - Google Patents
Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä Download PDFInfo
- Publication number
- FI3565551T3 FI3565551T3 FIEP18735813.0T FI18735813T FI3565551T3 FI 3565551 T3 FI3565551 T3 FI 3565551T3 FI 18735813 T FI18735813 T FI 18735813T FI 3565551 T3 FI3565551 T3 FI 3565551T3
- Authority
- FI
- Finland
- Prior art keywords
- vaborbactam
- subject
- use according
- meropenem
- combination
- Prior art date
Links
- IOOWNWLVCOUUEX-WPRPVWTQSA-N 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid Chemical compound OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1 IOOWNWLVCOUUEX-WPRPVWTQSA-N 0.000 title claims 19
- 229950007158 vaborbactam Drugs 0.000 title claims 19
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 title claims 7
- 229960002260 meropenem Drugs 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 6
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 206010037597 Pyelonephritis acute Diseases 0.000 claims 8
- 201000001555 acute pyelonephritis Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 241000588697 Enterobacter cloacae Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 241000588770 Proteus mirabilis Species 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims 1
- 229960003865 tazobactam Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444238P | 2017-01-09 | 2017-01-09 | |
| US201762513936P | 2017-06-01 | 2017-06-01 | |
| PCT/US2018/012839 WO2018129479A1 (en) | 2017-01-09 | 2018-01-08 | Methods of treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3565551T3 true FI3565551T3 (fi) | 2024-06-18 |
Family
ID=62791302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18735813.0T FI3565551T3 (fi) | 2017-01-09 | 2018-01-08 | Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12478606B2 (enExample) |
| EP (2) | EP4212157A1 (enExample) |
| JP (2) | JP7436206B2 (enExample) |
| KR (2) | KR102768209B1 (enExample) |
| CN (1) | CN110402139A (enExample) |
| AU (1) | AU2018205327B2 (enExample) |
| BR (1) | BR112019014089A2 (enExample) |
| CA (1) | CA3048650A1 (enExample) |
| CL (2) | CL2019001918A1 (enExample) |
| CO (1) | CO2019008575A2 (enExample) |
| DK (1) | DK3565551T3 (enExample) |
| ES (1) | ES2979266T3 (enExample) |
| FI (1) | FI3565551T3 (enExample) |
| HU (1) | HUE066805T2 (enExample) |
| MX (2) | MX390529B (enExample) |
| NZ (1) | NZ755141A (enExample) |
| PH (1) | PH12019501606A1 (enExample) |
| PL (1) | PL3565551T3 (enExample) |
| PT (1) | PT3565551T (enExample) |
| SG (1) | SG11201906226YA (enExample) |
| WO (1) | WO2018129479A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478606B2 (en) | 2017-01-09 | 2025-11-25 | Melinta Subsidiary Corp. | Methods of treating bacterial infections |
| AU2018345317B2 (en) * | 2017-10-03 | 2024-10-24 | Melinta Therapeutics, Inc. | Methods of treating bacterial infections |
| WO2022026993A1 (en) * | 2020-07-27 | 2022-02-03 | Northwestern University | Antimicrobial choice algorithm for urinary tract infections |
| CN117940127A (zh) * | 2022-07-05 | 2024-04-26 | 塞戈瑞·弗拉基米罗维奇·西多连科 | 治疗多种耐药细菌感染的制剂 |
| WO2024018372A2 (en) * | 2022-07-20 | 2024-01-25 | Sri Sathya Sai Institute Of Higher Learning | A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy |
| JP2026517813A (ja) * | 2023-05-02 | 2026-06-02 | シプラ・リミテッド | 医薬配合剤及び抗菌剤を含むその組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN105393011A (zh) * | 2013-05-15 | 2016-03-09 | 舍弗勒技术股份两合公司 | 减少阻力的离合器板 |
| WO2016172208A1 (en) | 2015-04-24 | 2016-10-27 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US9949995B2 (en) | 2015-09-04 | 2018-04-24 | Case Western Reserve University | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors |
| US12478606B2 (en) | 2017-01-09 | 2025-11-25 | Melinta Subsidiary Corp. | Methods of treating bacterial infections |
-
2018
- 2018-01-08 US US16/474,487 patent/US12478606B2/en active Active
- 2018-01-08 PL PL18735813.0T patent/PL3565551T3/pl unknown
- 2018-01-08 EP EP23159896.2A patent/EP4212157A1/en active Pending
- 2018-01-08 AU AU2018205327A patent/AU2018205327B2/en active Active
- 2018-01-08 BR BR112019014089A patent/BR112019014089A2/pt not_active Application Discontinuation
- 2018-01-08 NZ NZ755141A patent/NZ755141A/en unknown
- 2018-01-08 FI FIEP18735813.0T patent/FI3565551T3/fi active
- 2018-01-08 PT PT187358130T patent/PT3565551T/pt unknown
- 2018-01-08 DK DK18735813.0T patent/DK3565551T3/da active
- 2018-01-08 KR KR1020197023321A patent/KR102768209B1/ko active Active
- 2018-01-08 SG SG11201906226YA patent/SG11201906226YA/en unknown
- 2018-01-08 JP JP2019537269A patent/JP7436206B2/ja active Active
- 2018-01-08 ES ES18735813T patent/ES2979266T3/es active Active
- 2018-01-08 EP EP18735813.0A patent/EP3565551B1/en active Active
- 2018-01-08 HU HUE18735813A patent/HUE066805T2/hu unknown
- 2018-01-08 CN CN201880006135.5A patent/CN110402139A/zh active Pending
- 2018-01-08 KR KR1020247028886A patent/KR20240133785A/ko not_active Ceased
- 2018-01-08 CA CA3048650A patent/CA3048650A1/en active Pending
- 2018-01-08 MX MX2019008281A patent/MX390529B/es unknown
- 2018-01-08 WO PCT/US2018/012839 patent/WO2018129479A1/en not_active Ceased
-
2019
- 2019-07-09 PH PH12019501606A patent/PH12019501606A1/en unknown
- 2019-07-09 MX MX2022001704A patent/MX2022001704A/es unknown
- 2019-07-09 CL CL2019001918A patent/CL2019001918A1/es unknown
- 2019-08-06 CO CONC2019/0008575A patent/CO2019008575A2/es unknown
-
2020
- 2020-07-17 CL CL2020001886A patent/CL2020001886A1/es unknown
-
2022
- 2022-11-07 JP JP2022178016A patent/JP2023012538A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019008281A (es) | 2019-12-02 |
| KR20240133785A (ko) | 2024-09-04 |
| CO2019008575A2 (es) | 2019-08-30 |
| EP3565551A1 (en) | 2019-11-13 |
| KR102768209B1 (ko) | 2025-02-18 |
| US20190336475A1 (en) | 2019-11-07 |
| EP3565551B1 (en) | 2024-03-20 |
| PH12019501606A1 (en) | 2020-06-15 |
| MX2022001704A (es) | 2022-03-11 |
| WO2018129479A1 (en) | 2018-07-12 |
| SG11201906226YA (en) | 2019-08-27 |
| CL2020001886A1 (es) | 2020-12-18 |
| CN110402139A (zh) | 2019-11-01 |
| JP2023012538A (ja) | 2023-01-25 |
| EP4212157A1 (en) | 2023-07-19 |
| US12478606B2 (en) | 2025-11-25 |
| KR20190104385A (ko) | 2019-09-09 |
| CL2019001918A1 (es) | 2020-02-14 |
| EP3565551A4 (en) | 2020-09-23 |
| ES2979266T3 (es) | 2024-09-25 |
| PT3565551T (pt) | 2024-06-14 |
| JP2020504154A (ja) | 2020-02-06 |
| BR112019014089A2 (pt) | 2020-02-04 |
| JP7436206B2 (ja) | 2024-02-21 |
| DK3565551T3 (da) | 2024-06-17 |
| AU2018205327B2 (en) | 2023-11-30 |
| AU2018205327A1 (en) | 2019-07-25 |
| PL3565551T3 (pl) | 2024-09-23 |
| CA3048650A1 (en) | 2018-07-12 |
| NZ755141A (en) | 2023-01-27 |
| HUE066805T2 (hu) | 2024-09-28 |
| MX390529B (es) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504154A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| Mentzelopoulos et al. | Intermittent recruitment with high-frequency oscillation/tracheal gas insufflation in acute respiratory distress syndrome | |
| JP2016516016A5 (enExample) | ||
| US9549904B2 (en) | Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin | |
| RU2013123646A (ru) | Комбинированная композиция | |
| JP2017534618A5 (enExample) | ||
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| WO2023231730A3 (zh) | 使用mazdutide的治疗方法 | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| US20100158857A1 (en) | Compositions and methods for the inhibition of endothelial nitric oxide synthase activity | |
| GB2514863A (en) | A method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin | |
| TWI472519B (zh) | 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能 | |
| Keskin et al. | Kounis syndrome presenting with acute inferior wall myocardial infarction and cardiogenic shock secondary to intravenous ampicillin/sulbactam administration | |
| ZA202212502B (en) | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis | |
| US20210301006A1 (en) | Methods of treating acute respiratory distress syndrome | |
| EP4132485B1 (en) | Phenol for use in the treatment of coronavirus induced dyspnoea | |
| Dumbarton et al. | Prolonged methylene blue infusion in refractory septic shock: a case report Perfusion prolongée de bleu de méthylene dans un cas de choc septique réfractaire: une présentation de cas | |
| CN103142611B (zh) | 一种组合物产品在治疗细菌感染的制药应用 | |
| CN116531387A (zh) | 新对叶百部碱在制备治疗肺动脉高压的药物中的应用 | |
| WO2024054226A1 (en) | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment | |
| Kaplan et al. | Effect of lidocaine on the hematopoietic properties of recombinant human erythropoietin in the uremic rat | |
| JP2023526790A5 (enExample) | ||
| Kopp et al. | Evidence-based medicine in ARDS: what is really proven? |